Confronto

CagriSema vs. Pramlintid

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Metabolico

N. CAS

nessun dato

151126-32-8

Peso molecolare

nessun dato

3949.4 g/mol

Emivita

nessun dato

Sequenza

nessun dato

Meccanismo d'azione

CagriSema

CagriSema combines two satiety pathways in one weekly injection: the amylin analogue cagrilintide and the GLP-1 agonist semaglutide. Both suppress appetite and food intake — together more than either component alone.

Pramlintid

Pramlintide mimics the beta-cell hormone amylin, which is co-secreted with insulin. It slows gastric emptying, suppresses postprandial glucagon release and promotes satiety — thereby blunting post-meal blood-glucose spikes.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	CagriSema	Pramlintid
Germania	Non approvato	Non approvato
Stati Uniti	Non approvato	Su prescrizione

Voci complete

Frequently asked questions

What is the difference between CagriSema and Pramlintid?: CagriSema is classified as "Metabolico", while Pramlintid is classified as "Metabolico". CagriSema: CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes. Pramlintid: Pramlintide is a synthetic analog of the hormone amylin. It is used as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes and, among other things, slows gastric emptying. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, CagriSema or Pramlintid?: The highest available evidence level is "RCT sull'uomo" for CagriSema and "RCT sull'uomo" for Pramlintid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of CagriSema and Pramlintid in Germany and the United States?: Germania: CagriSema — Non approvato, Pramlintid — Non approvato. Stati Uniti: CagriSema — Non approvato, Pramlintid — Su prescrizione. These are factual summaries with source and review date on the individual pages.

Country

CagriSema

Pramlintid

Germania

Non approvato

Stati Uniti

Non approvato

Su prescrizione

Frequently asked questions

What is the difference between CagriSema and Pramlintid?

CagriSema is classified as "Metabolico", while Pramlintid is classified as "Metabolico". CagriSema: CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes. Pramlintid: Pramlintide is a synthetic analog of the hormone amylin. It is used as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes and, among other things, slows gastric emptying. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, CagriSema or Pramlintid?

The highest available evidence level is "RCT sull'uomo" for CagriSema and "RCT sull'uomo" for Pramlintid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of CagriSema and Pramlintid in Germany and the United States?

Germania: CagriSema — Non approvato, Pramlintid — Non approvato. Stati Uniti: CagriSema — Non approvato, Pramlintid — Su prescrizione. These are factual summaries with source and review date on the individual pages.